Cerus Corporation develops and commercializes pathogen reduction systems for blood components used in transfusions. The company's core product is the INTERCEPT Blood System, a proprietary technology platform designed to inactivate blood-borne pathogens in donated blood products. The company offers INTERCEPT systems for platelets, plasma, red blood cells, and cryoprecipitated fibrinogen complex, with the latter used in treatment of bleeding disorders associated with fibrinogen deficiency.
The company generates revenue primarily through the sale of platelet and plasma systems, which represent its main commercial focus. The INTERCEPT Blood System for red blood cells and cryoprecipitate products comprise additional revenue streams. Cerus sells its products through a combination of direct sales personnel and distributor networks across multiple geographies.
The company operates with approximately 614 full-time employees and maintains headquarters in Concord, California. Its distribution network spans the United States, Europe, the Commonwealth of Independent States, the Middle East, and Latin America, reflecting a global commercial presence in the blood safety market.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.11 | $-0.11 | +47.6% | |
| 2023 | $-0.21 | $-0.21 | +12.5% | |
| 2022 | $-0.24 | $-0.24 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | $-0.12 | $-0.12 | +0.0% | |
| 2018 | $-0.12 | $-0.12 | -20.0% | |
| 2017 | $-0.10 | $-0.10 | +23.1% | |
| 2016 | $-0.13 | $-0.13 | +13.3% | |
| 2015 | $-0.15 | $-0.15 | +42.3% | |
| 2014 | $-0.26 | $-0.26 | -160.0% | |
| 2013 | $-0.10 | $-0.08 | -42.9% | |
| 2012 | $-0.07 | $-0.03 | +80.0% | |
| 2011 | $-0.35 | $-0.35 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-02-26 | 0000950170-25-027906 | SEC ↗ |
| 2023-12-31 | 2024-03-05 | 0000950170-24-026195 | SEC ↗ |
| 2022-12-31 | 2023-03-01 | 0000950170-23-005558 | SEC ↗ |
| 2021-12-31 | 2022-02-22 | 0000950170-22-001641 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001564590-21-008958 | SEC ↗ |
| 2019-12-31 | 2020-02-21 | 0001564590-20-005756 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0001564590-19-004542 | SEC ↗ |
| 2017-12-31 | 2018-03-08 | 0001564590-18-004969 | SEC ↗ |
| 2016-12-31 | 2017-03-08 | 0001564590-17-003711 | SEC ↗ |
| 2015-12-31 | 2016-03-09 | 0001193125-16-498617 | SEC ↗ |
| 2014-12-31 | 2015-03-16 | 0001193125-15-094038 | SEC ↗ |
| 2013-12-31 | 2014-03-07 | 0001193125-14-089394 | SEC ↗ |
| 2012-12-31 | 2013-03-12 | 0001193125-13-103031 | SEC ↗ |
| 2011-12-31 | 2012-03-05 | 0001193125-12-096720 | SEC ↗ |
| 2010-12-31 | 2011-03-16 | 0001193125-11-068699 | SEC ↗ |
| 2009-12-31 | 2010-03-11 | 0001193125-10-052917 | SEC ↗ |